{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=21",
    "query": {
      "condition": "Randomized Controlled Study",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 15129,
    "total_pages": 1513,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Randomized+Controlled+Study&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T16:35:11.830Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04671082",
      "title": "Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Back Muscle Spasm",
        "Back Pain",
        "Back Strain",
        "Back Spasm Upper",
        "Muscle Spasm",
        "Acute Pain"
      ],
      "interventions": [
        {
          "name": "Tolperisone Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurana Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 1004,
      "start_date": "2020-12-15",
      "completion_date": "2022-03-21",
      "has_results": false,
      "last_update_posted_date": "2022-03-22",
      "last_synced_at": "2026-10-23T16:35:11.830Z",
      "location_count": 56,
      "location_summary": "Surprise, Arizona • Little Rock, Arkansas • Canoga Park, California + 51 more",
      "locations": [
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04671082"
    },
    {
      "nct_id": "NCT01465282",
      "title": "Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis Vulgaris"
      ],
      "interventions": [
        {
          "name": "CT327 0.05%",
          "type": "DRUG"
        },
        {
          "name": "CT327 0.1%",
          "type": "DRUG"
        },
        {
          "name": "CT327 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Creabilis SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2011-12",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2013-03-08",
      "last_synced_at": "2026-10-23T16:35:11.830Z",
      "location_count": 8,
      "location_summary": "Hotsprings, Arkansas • San Ramon, California • Bay City, Michigan + 5 more",
      "locations": [
        {
          "city": "Hotsprings",
          "state": "Arkansas"
        },
        {
          "city": "San Ramon",
          "state": "California"
        },
        {
          "city": "Bay City",
          "state": "Michigan"
        },
        {
          "city": "Fridley",
          "state": "Minnesota"
        },
        {
          "city": "South Euclid",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01465282"
    },
    {
      "nct_id": "NCT01107496",
      "title": "Evaluation of Immediate-Release Viloxazine in Adults With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "IR Viloxazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 52,
      "start_date": "2010-06",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-10-23T16:35:11.830Z",
      "location_count": 4,
      "location_summary": "Bradenton, Florida • Libertyville, Illinois • Owensboro, Kentucky + 1 more",
      "locations": [
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Libertyville",
          "state": "Illinois"
        },
        {
          "city": "Owensboro",
          "state": "Kentucky"
        },
        {
          "city": "Herndon",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01107496"
    },
    {
      "nct_id": "NCT00421603",
      "title": "A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine Dependence"
      ],
      "interventions": [
        {
          "name": "Adderall-XR and Topiramate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 81,
      "start_date": "2007-02",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2019-04-24",
      "last_synced_at": "2026-10-23T16:35:11.830Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00421603"
    },
    {
      "nct_id": "NCT01371305",
      "title": "STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis (IPF)"
      ],
      "interventions": [
        {
          "name": "BG00011",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 41,
      "start_date": "2012-07-16",
      "completion_date": "2017-03-31",
      "has_results": true,
      "last_update_posted_date": "2020-02-28",
      "last_synced_at": "2026-10-23T16:35:11.830Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01371305"
    },
    {
      "nct_id": "NCT06102005",
      "title": "Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Lunsekimig",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 685,
      "start_date": "2023-10-16",
      "completion_date": "2026-03-11",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-10-23T16:35:11.830Z",
      "location_count": 48,
      "location_summary": "Scottsdale, Arizona • Yuma, Arizona • Lancaster, California + 41 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06102005"
    },
    {
      "nct_id": "NCT01462851",
      "title": "A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-05297909 25 mg",
          "type": "DRUG"
        },
        {
          "name": "PF-05297909 100 mg",
          "type": "DRUG"
        },
        {
          "name": "PF-05297909 250 mg",
          "type": "DRUG"
        },
        {
          "name": "PF-05297909 525 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 51,
      "start_date": "2011-09",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2012-03-13",
      "last_synced_at": "2026-10-23T16:35:11.830Z",
      "location_count": 2,
      "location_summary": "Glendale, California • New Haven, Connecticut",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01462851"
    },
    {
      "nct_id": "NCT01780129",
      "title": "Polydatin Injectable (HW6) for Shock Treatment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Shock, Hemorrhagic",
        "Shock, Traumatic",
        "Shock, Septic"
      ],
      "interventions": [
        {
          "name": "Polydatin Injectable",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neptunus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 240,
      "start_date": "2013-02",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-30",
      "last_synced_at": "2026-10-23T16:35:11.830Z",
      "location_count": 1,
      "location_summary": "Newark, Delaware",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01780129"
    },
    {
      "nct_id": "NCT05451329",
      "title": "A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma, Open-Angle"
      ],
      "interventions": [
        {
          "name": "VVN539 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "VVN539 Ophthalmic Solution 0.04%",
          "type": "DRUG"
        },
        {
          "name": "VVN539 Ophthalmic Solution Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VivaVision Biotech, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2022-07-12",
      "completion_date": "2022-12-22",
      "has_results": true,
      "last_update_posted_date": "2024-01-17",
      "last_synced_at": "2026-10-23T16:35:11.830Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05451329"
    },
    {
      "nct_id": "NCT00891202",
      "title": "A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gaucher Disease, Type 1"
      ],
      "interventions": [
        {
          "name": "Eliglustat tartrate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2009-11",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-10-23T16:35:11.830Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Decatur, Georgia + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00891202"
    }
  ]
}